247 related articles for article (PubMed ID: 1484319)
41. [The problems of early diagnosis of diffuse malignant mesothelioma from the pathologo-anatomic view].
Schultz M; Kühne W
Zentralbl Pathol; 1992 Apr; 138(2):85-90. PubMed ID: 1610769
[TBL] [Abstract][Full Text] [Related]
42. Parathyroid hormone-related protein antigen localization distinguishes between mesothelioma and adenocarcinoma of the lung.
Clark SP; Chou ST; Martin TJ; Danks JA
J Pathol; 1995 Jun; 176(2):161-5. PubMed ID: 7636626
[TBL] [Abstract][Full Text] [Related]
43. The "Brescia panel" (Claudin-4 and BRCA-associated protein 1) in the differential diagnosis of mesotheliomas with epithelioid features versus metastatic carcinomas.
Bernardi L; Bizzarro T; Pironi F; Szymczuk S; Buda R; Fabbri E; Di Claudio G; Rossi G
Cancer Cytopathol; 2021 Apr; 129(4):275-282. PubMed ID: 33045147
[TBL] [Abstract][Full Text] [Related]
44. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12.
Lee I; Radosevich JA; Chejfec G; Ma YX; Warren WH; Rosen ST; Gould VE
Am J Pathol; 1986 Jun; 123(3):497-507. PubMed ID: 3717302
[TBL] [Abstract][Full Text] [Related]
45. [Small-cell mesothelioma of the pleura: description of a case].
Cavazza A; Rossi G; Agostini L; Facciolongo N; De Marco L; Putrino I; Gardini G
Pathologica; 2002 Oct; 94(5):247-52. PubMed ID: 12417972
[TBL] [Abstract][Full Text] [Related]
46. Immunohistochemical properties of malignant mesothelioma cells in histologic and cytologic specimens.
Motoyama T; Watanabe T; Okazaki E; Tanaka N; Watanabe H
Acta Cytol; 1995; 39(2):164-70. PubMed ID: 7534025
[TBL] [Abstract][Full Text] [Related]
47. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers.
Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S
J Clin Pathol; 2013 Oct; 66(10):847-53. PubMed ID: 23814259
[TBL] [Abstract][Full Text] [Related]
48. [Pathology of primary tumours of the pleura].
Junker K; Krismann M
Zentralbl Chir; 2008 Jun; 133(3):222-6. PubMed ID: 18563685
[TBL] [Abstract][Full Text] [Related]
49. Diagnostic utility of calretinin immunohistochemistry in cytologic cell block preparations.
Wieczorek TJ; Krane JF
Cancer; 2000 Oct; 90(5):312-9. PubMed ID: 11038429
[TBL] [Abstract][Full Text] [Related]
50. p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure.
Isik R; Metintas M; Gibbs AR; Metintas S; Jasani B; Oner U; Harmanci E; Demircan S; Işiksoy S
Respir Med; 2001 Jul; 95(7):588-93. PubMed ID: 11453316
[TBL] [Abstract][Full Text] [Related]
51. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3).
Szpak CA; Johnston WW; Roggli V; Kolbeck J; Lottich SC; Vollmer R; Thor A; Schlom J
Am J Pathol; 1986 Feb; 122(2):252-60. PubMed ID: 2418688
[TBL] [Abstract][Full Text] [Related]
52. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies.
Cagle PT; Churg A
Arch Pathol Lab Med; 2005 Nov; 129(11):1421-7. PubMed ID: 16253023
[TBL] [Abstract][Full Text] [Related]
53. The separation of benign and malignant mesothelial proliferations.
Churg A; Galateau-Salle F
Arch Pathol Lab Med; 2012 Oct; 136(10):1217-26. PubMed ID: 23020727
[TBL] [Abstract][Full Text] [Related]
54. [Detection of p16 by fluorescence in-situ hybridization and immunohistochemistry in malignant mesothelioma].
Liu Y; Chen X; Ding N; Xu W; Yang H; Chen X
Zhonghua Bing Li Xue Za Zhi; 2015 Apr; 44(4):262-5. PubMed ID: 25975910
[TBL] [Abstract][Full Text] [Related]
55. [Morphological diagnostics of malignant pleural mesothelioma].
Junker K; Müller KM
Pathologe; 2014 Nov; 35(6):586-90. PubMed ID: 25304423
[TBL] [Abstract][Full Text] [Related]
56. The separation of benign and malignant mesothelial proliferations.
Churg A; Colby TV; Cagle P; Corson J; Gibbs AR; Gilks B; Grimes M; Hammar S; Roggli V; Travis WD
Am J Surg Pathol; 2000 Sep; 24(9):1183-200. PubMed ID: 10976692
[TBL] [Abstract][Full Text] [Related]
57. [BRCA1 associated protein 1 (BAP1) expression in pleural diffuse malignant mesothelioma: A comparative cytological and histological analyses on 50 patients].
Jaouen A; Thivolet-Bejui F; Chalabreysse L; Piaton E; Traverse-Glehen A; Isaac S; Decaussin-Petrucci M; Depaepe L; Fontaine J; Remy I; Maury JM; Brevet M
Ann Pathol; 2016 Apr; 36(2):111-9. PubMed ID: 26995100
[TBL] [Abstract][Full Text] [Related]
58. Pleural biopsy in the diagnosis of malignant mesothelioma.
Herbert A; Gallagher PJ
Thorax; 1982 Nov; 37(11):816-21. PubMed ID: 7163999
[TBL] [Abstract][Full Text] [Related]
59. [Mesothelioma and mesothelial hyperplasia].
Li LY; Luo WC; Zhu YJ
Zhonghua Nei Ke Za Zhi; 1990 Jun; 29(6):328-31, 381. PubMed ID: 2269029
[TBL] [Abstract][Full Text] [Related]
60. [Differential diagnosis of preneoplastic lesions of the pleura and of early mesothelioma: immunohistochemical and morphological findings].
Krismann M; Thattamparambil P; Simon F; Johnen G
Pathologe; 2006 Mar; 27(2):99-105. PubMed ID: 16435096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]